Transmission of SARS-COV-2 Infections in Households - Tennessee and Wisconsin, April-September 2020.
Adolescent
Adult
Aged
Betacoronavirus
/ isolation & purification
COVID-19
COVID-19 Testing
Child
Child, Preschool
Clinical Laboratory Techniques
Coronavirus Infections
/ diagnosis
Family Characteristics
Female
Humans
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ diagnosis
Prospective Studies
SARS-CoV-2
Tennessee
/ epidemiology
Wisconsin
/ epidemiology
Young Adult
Journal
MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429
Informations de publication
Date de publication:
06 Nov 2020
06 Nov 2020
Historique:
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
11
11
2020
Statut:
epublish
Résumé
Improved understanding of transmission of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), within households could aid control measures. However, few studies have systematically characterized the transmission of SARS-CoV-2 in U.S. households (1). Previously reported transmission rates vary widely, and data on transmission rates from children are limited. To assess household transmission, a case-ascertained study was conducted in Nashville, Tennessee, and Marshfield, Wisconsin, commencing in April 2020. In this study, index patients were defined as the first household members with COVID-19-compatible symptoms who received a positive SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) test result, and who lived with at least one other household member. After enrollment, index patients and household members were trained remotely by study staff members to complete symptom diaries and obtain self-collected specimens, nasal swabs only or nasal swabs and saliva samples, daily for 14 days. For this analysis, specimens from the first 7 days were tested for SARS-CoV-2 using CDC RT-PCR protocols.
Identifiants
pubmed: 33151916
doi: 10.15585/mmwr. mm6944e1
pmc: PMC7643897
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1631-1634Subventions
Organisme : NIAID NIH HHS
ID : K24 AI148459
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001078
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001083
Pays : United States
Déclaration de conflit d'intérêts
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Carlos G. Grijalva reports personal consulting fees from Sanofi, Merck, and Pfizer; grants from Sanofi, Campbell Alliance, the National Institutes of Health, the Agency for HealthCare Research and Quality, and a contract from the Food and Drug Administration, outside the submitted work. Natasha B. Halasa reports grants from Sanofi and Quidel and personal fees from Genetech, outside the submitted work. No other potential conflicts of interest were disclosed.
Références
Clin Infect Dis. 2020 Nov 19;71(16):2099-2108
pubmed: 32392331
JAMA Netw Open. 2020 Jul 1;3(7):e2016382
pubmed: 32697321
Clin Infect Dis. 2021 Oct 5;73(7):1805-1813
pubmed: 33185244
N Engl J Med. 2020 Nov 26;383(22):e120
pubmed: 32997903
MMWR Morb Mortal Wkly Rep. 2020 Mar 06;69(9):245-246
pubmed: 32134909
BMJ. 2020 Aug 14;370:m3181
pubmed: 32816710
J Infect. 2020 Dec;81(6):979-997
pubmed: 32858069
J Infect. 2020 Jul;81(1):179-182
pubmed: 32283139
BMJ Glob Health. 2020 May;5(5):
pubmed: 32467353
N Engl J Med. 2020 Sep 24;383(13):1283-1286
pubmed: 32857487